AJM300

Research use only, not for human use.

AJM300 (AJM 300, AJM-300) is a novel potent, selective, oraaly available alpha 4 integrin antagonist fortreatment of active ulcerative colitis.

AJM300 (AJM 300, AJM-300) is a novel potent, selective, oraaly available alpha 4 integrin antagonist fortreatment of active ulcerative colitis.Other Indication Phase 3 Clinical.

——

Animal Model:Mouse model of colitis induced by adoptive transfer of IL-10 deficient CD4+ T cells Dosage:Diet; 0.03, 0.1, 0.3 or 1% Administration:For 15 days Result:Had a histological improvement in epithelial cell hyperplasia, reduced inflammatory cell infiltration and a decrease in mucus production.Prevented an increase in the colon weight in a model of colitis induced by adoptive transfer of CD4+CD45RB high T cells.

AJM 300 | AJM-300

Cell Cycle/DNA Damage

Integrin

Integrin

Other Indications

Other Disease

401905-67-7

569.439

C28H26Cl2N4O5

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (175.61 mM)

O=C(OC)[C@H](CC1=CC=C(N2C(N(C)C3=C(C=C(N(C)C)C=C3)C2=O)=O)C=C1)NC(C4=C(Cl)C=CC=C4Cl)=O

methyl (S)-2-(2,6-dichlorobenzamido)-3-(4-(6-(dimethylamino)-1-methyl-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)phenyl)propanoate

(-20℃)

With Ice Pack

≥ 2 years